CN108384856A

CN108384856A - Regulate and control the non-coding RNA and application thereof of C4B gene expressions

Info

Publication number: CN108384856A
Application number: CN201810193777.2A
Authority: CN
Inventors: 石小峰; 常鹏; 马翠
Original assignee: Beijing Medintell Bioinformatic Technology Co Ltd
Current assignee: Qingdao Yangshen Biomedical Co Ltd
Priority date: 2018-03-09
Filing date: 2018-03-09
Publication date: 2018-08-10
Anticipated expiration: 2038-03-09
Also published as: CN108384856B

Abstract

The present invention relates to the non-coding RNAs and application thereof of regulation and control C4B gene expressions, more particularly relate to non-coding RNA-ENSG00000233627, miR 1197, miR 1269a, 182 miR 5p and its application in diagnosis and treatment bone and flesh tumor metastasis.Inventor is to bone and flesh tumor metastasis patient, primary patient and normal population, from mRNA to miRNA various dimensions research is carried out to lncRNA, lncRNA and miRNA with the closely related C4B genes of bone and flesh tumor metastasis, regulation and control C4B gene expressions is provided, good thinking is provided for osteosarcoma Mechanism Study, new molecular marker is provided for osteosarcoma clinical diagnosis, is had great importance.

Description

Regulate and control the non-coding RNA and application thereof of C4B gene expressions

Technical field

The present invention relates to molecular biology fields, are specifically related to the non-coding RNA and its use of regulation and control C4B gene expressions On the way, more particularly relate to non-coding RNA-ENSG00000233627, miR-1197, miR-1269a, miR-182-5p and its Application in diagnosis and treatment bone and flesh tumor metastasis.

Background technology

C4B genes are located at No. six the short arm of a chromosome, and existing that researches show that it is related to esophageal squamous cell carcinoma transfer (Clinical significance of mannose-binding lectin-associated serine protease- 2expression in esophageal squamous cell carcinoma, Int.J.Cancer:118,2930-2935 (2006)).The human gene overwhelming majority can transcribe, but most of product is non-coding RNA (ncRNA), and part ncRNA can Vital movement is played regulatory role by influencing gene and epigenetics, long-chain non-coding RNA (lncRNA) and Microrna (miRNA) it is two class of most important one, they play an important role in a variety of vital movements.

LncRNA is that a kind of transcript length is more than 200nt, lack effectively open reading frame, not coding protein RNA molecule.It is catalyzed transcription synthesis by RNA polymerase II, is distributed mainly on nucleus, is present in cytoplasm on a small quantity.Research It was found that lncRNA tends to be folded into thermodynamically stable two level more or more advanced structure functions, part lncRNA passes through Montage becomes with the polyA tails and promoter structure similar to mRNA, and it can be dynamic in histoorgan atomization Expression and different montage modes, therefore lncRNA has time and Region-specificity.LncRNA presses transcript location not at present It is same to fall into 5 types:Positioned at the lncRNA of intergenic region；Natural antisense chain lncRNA；Include sub-district lncRNA；Positive-sense strand lncRNA；Two-way lncRNA.MiRNA is a kind of short sequence of non-coding for not having Open reading frame, length for 18-25nt RNA is widely present in eucaryote.It is hydroxyl that, which there are the ends phosphate group 3' at the ripe ends miRNA 5', this feature makes It with most of oligonucleotides and the degradation fragment of function RNA be distinguished conservatives of the overwhelming majority miRNA with height, Timing and tissue characteristics.

It is many research shows that the important link that miRNA, which is lncRNA, to play a role, in the sick cell of many diseases There are certain quantitative relations with certain miRNA by the middle a certain lncRNA of discovery, and the hair of their quantity variation and relevant disease Closely related (Functional interactions among microRNAs and long noncoding are opened up in hair tonic RNAs, Semin Cell Dev Biol, 2014,34:9-14).LncRNA and miRNA has a respective regulated and control network, but two The regulated and control network of person be not it is self-existent, many times in a kind of occurrence and development of disease lncRNA and miRNA tune Control is interdependence, is interweaved, and together forms a complicated regulated and control network.

Once the expression number of the miRNA of high-flux sequence research metastatic bone sarcoma patients and Healthy People was used before applicant According to discovery miR-4520-3p, miR-1299 (ZL2016100688631 and ZL related to bone and flesh tumor metastasis 2016100686566), in the application, inventor further to bone and flesh tumor metastasis patient, primary patient and normal population, from MRNA to miRNA to lncRNA carries out various dimensions research.The present invention provides and the closely related C4B genes of bone and flesh tumor metastasis, tune The lncRNA and miRNA for controlling C4B gene expressions, good thinking is provided for osteosarcoma Mechanism Study, is osteosarcoma clinical diagnosis New molecular marker is provided, is had great importance.

Invention content

The purpose of the present invention is to provide detection C4B genes and the non-coding RNA preparation for regulating and controlling its expression to prepare diagnosis Application in osteosarcoma transfering reagent, the non-coding RNA are lncRNA and/or miRNA.

Further, lncRNA ENSG00000233627；MiRNA is miR-1197, miR-1269a or miR-182-5p.

The sequence of ENSG00000233627 is shown in sequence table SEQ ID NO 1.

The sequence of miR-1197 is shown in sequence table SEQ ID NO 2.

The sequence of miR-1269a is shown in sequence table SEQ ID NO 3.

The sequence of miR-182-5p is shown in sequence table SEQ ID NO 4.

Further, diagnosis osteosarcoma transfering reagent includes based on high-flux sequence method and/or being based on quantifying PCR method And/or based on C4B, ENSG00000233627, miR-1197, miR-1269a or miR- in probing procedure detection sample 182-5p transcribes or is detected based on immunologic detection method the expression of C4B albumen in sample.

Preferably, using northern hybridizing methods, miRNA chip of expression spectrum, ribozyme protection analytical technology, RAKE methods, C4B, ENSG00000233627, miR-1197, miR-1269a in situ hybridization, bead-based flow-cytometry detection sample Or the transcription of miR-182-5p；Using the expression of C4B albumen in ELISA and/or colloidal gold strip detection sample.

Preferably, include specific amplification C4B, ENSG00000233627, miR-1197, miR- based on quantifying PCR method The primer of 1269a or miR-182-5p；Based on probing procedure include with C4B, ENSG00000233627, miR-1197, The probe of the nucleic acid array hybridizing of miR-1269a or miR-182-5p；The immunologic detection method includes and C4B protein-specifics In conjunction with antibody.

The purpose of the present invention is to provide a kind of prevention osteosarcoma transfering reagent, including lower miR-1269a transcription and/ Or inhibit the active reagent of miR-1269a, or lower the transcription and/or inhibition of ENSG00000233627 The active reagent of ENSG00000233627, or raise the transcription of miR-1197 or miR-182-5p and/or promote miR- The active reagents of 1197 or miR-182-5p.

Preferably, using antisense oligonucleotides, miRNA inhibitor, antagomiRs, miRNA sponge, miRNA The method of Erasers, Target Masking and/or multiple target point antisense oligonucleotides lowers the transcription and/or resistance of miR-1269a The activity of disconnected miR-1269a.

Preferably, using the acquired technology of microRNA functions and/or gene specific miRMimics skills based on RNA Art raises the transcription of miR-1197 or miR-182-5p and/or promotes the activity of miR-1197 or miR-182-5p.It is preferred that artificial It synthesizes short hairpin RNA or raises miR-1197 or miR-182-5p by regulating and controlling promoter.

Preferably, the transcription and/or inhibition of ENSG00000233627 are lowered using siRNA or structure interference carrier The activity of ENSG00000233627.

Further, the reagent also includes receptible carrier in pharmacy.

The purpose of the present invention is to provide above-mentioned prevention osteosarcoma transfering reagent prepare treatment osteosarcoma diversion medicaments or Application in preparation.

The purpose of the present invention is to provide above-mentioned bone and flesh tumor metastasis diagnostic preparations in preparing bone and flesh tumor metastasis diagnostic tool Application.

Definition：

The method of the expression of detection miRNA includes mainly based on high throughput sequencing technologies, is based on nucleotide at this stage The miRNA detection methods of hybridization and based on PCR.MiRNA detection methods based on probe hybridization technique are a kind of direct Detection Methods, Sample rna need not be expanded in advance, including northern hybridizing methods, miRNA chip of expression spectrum, ribozyme protection analysis skill The technologies such as art, RAKE methods, in situ hybridization, bead-based flow-cytometry.

(1) Northern hybridizes

Also known as Northern blot is most classical detection eucaryote RNA sizes, estimates the experimental method of its abundance.Base Present principles are as follows：MiRNA samples are fixed on carrier (such as silicon chip, microballoon or film) first, then miscellaneous with the probe by label It hands over, signal detection is carried out after washing extra hybridization probe；It can also be first fixed on carrier and target miRNA sequence complementation Then DNA probe hybridizes with the sample miRNA by label, then carries out signal detection.The method of signal label includes isotope Label, fluorescent marker and nano gold mark etc..

(2) miRNA chip of expression spectrum

Principle is equally using the target molecule on label probe detection solid support.Pass through miRNA in design chips Gene and internalcontrol sequence, can Accurate Analysis go out the expression of corresponding miRNA in sample.Genetic chip has the excellent of high throughput Point can once detect whole expression of hundreds of genes in same sample.The liquid-phase chip that Luminex companies develop (Liquid chip) is also known as multifunctional suspending dot matrix (Multi analytesuspension array, MASA), be it is new Generation biochip technology.Liquid-phase chip system is made of many spherulas for main matrix, is fixed with not on each spherula Same probe molecule, in order to distinguish different probes, each is used for the sphere matrix of label probe all with there are one unique Color numbers constitute liquid-phase chip system as soon as these spherulas are suspended in a liquid-phase system.The system can be to same Multiple and different molecules in one trace sample are carried out at the same time quick qualitative and quantitative analysis, and this detection technique is referred to as FMAP (Flexible multianalyte profiling) technology.Molecule hybridization carries out in aaerosol solution, detection speed pole Soon.

(3) ribozyme protection analytical technology (RPA)

The detection of miRNA can also use ribozyme to protect analytical technology, and the probe marked and RNA samples to be measured are mixed Close, hybridize after thermal denaturation, non-hybridized RNA and the single-chain nucleic acid enzymic digestion of extra probe, after heat inactivation nuclease purifying by Probe, colour developing is separated by electrophoresis finally by denaturation PAGE in the RNA molecule of protection.This new method based on solution hybridization is simple Quickly, high sensitivity, but be also only used for analyzing known miRNA.

(4) RAKE methods

RAKE methods (RNA primed array based Klenow emzyme) are the bases in miRNA microarray The Klenow segments of DNA polymerase i, the method for making miRNA hybridize with fixed DNA probe are utilized on plinth.RAKE can be sensitive MiRNA is specifically detected, suitable for largely quickly screening all known miRNA.It can be in specific cell and tumour Detect miRNA express spectra situations.Moreover, RAKE methods can also be from the tissue of the paraffin embedding secured by formalin It isolates miRNA and analyzes it, to analyze the door that miRNA opens hope from archive sample.

(5) in situ hybridization (in situ hybridization)

Hybridization in situ technique can intuitively understand miRNA expression ways, be a kind of easier of observation miRNA spatial and temporal expressions Method, normal mark mode include digoxin, biotin, fluorescent marker etc..In situ hybridization (Locked on the basis of locked nucleic acid Nucleic Acid (LNA) based in situ hybridization (LNA-ISH)) it is the more probe side of current application Formula.

(6) bead-based flow-cytometry (bead-based flow cytometry)

It is a kind of liquid-phase chip technology, FCM analysis is organically combined with chip technology, had concurrently by this method The features such as flux is big, detection speed is fast, high sensitivity and specificity are good.

(7) Real-Time Fluorescent Quantitative PCR Technique (Real-time PCR, RT-PCR)

Fluoroscopic examination PCR instrument can draw dynamic changing curve to the cumulative speed of extension increasing sequence during entire PCR.Anti- Answer the initial concentration of target sequence in mixed system bigger, it is desirable that the PCR cycle number for obtaining amplified production specific output is (general to use Specific threshold recurring number Ct is expressed) it is fewer.Since miRNA length is only 22nt, it is such that traditional qRT-PCR is not suitable for amplification Short segment.There are several real time quantitative PCR methods for miRNA, such as tailing method, neck ring method now.Neck ring method is a kind of Ideal miRNA detects qRT-PCR methods：Special loop-stem structure primer is designed first, using miRNA to be measured as template reverse transcription The first chains of cDNA are synthesized, which is stem Loop primer, and stem loop structure, which is opened, substantially increases the length of cDNA, then Real-time quantitative PCR amplification is carried out by template design primer of the cDNA of synthesis.QRT-PCR has specificity height, sensitivity good, fast A variety of advantages such as fast simple.

(8) PCR sequencing PCR

MiRNA known to major part is to be sequenced to find and identify by cDNA clone.The method needs first to build miRNA CDNA library, then carry out PCR amplification, amplified production is then cloned on expression vector and is sequenced.Takada develops one kind and changes Into amplification PCR cloning PCR (miRNA amplification profiling, mRAP), mRAP methods first connect at the 3 ' ends of miRNA Connector, then with the reverse transcription primer reverse transcription with connector complementation.Because specific reverse transcriptase has end deoxynucleotide Transferase active, some nucleotide (mainly deoxycytidylic acid) can be connected to 3 ' ends of the cDNA chains that reverse transcription goes out.When 5 ' End connector is added a pair of of general primer and can be realized and expand the PCR of cDNA with after poly (C) cohesive end annealing of cDNA chains Increase.Due to mRAP High sensitivities, the expression quantity of miRNA in clone and a small amount of tissue of sequencing technologies detection can be directly used.Label Sequence PCR cloning PCR is a kind of to have developed detection efficiency on the basis of serial analysis of gene expression (SAGE) technology higher MiRAGE (miRNA SAGE) PCR cloning PCR, the method can detect multiple by generating big sub-series by single sequencing reaction MiRNA, hence it is evident that improve detection efficiency.

High-flux sequence (High-throughput sequencing) is also known as next-generation sequencing technologies (nextgeneration sequencing) is the change to tradition sequencing revolution, once to hundreds of thousands to millions of DNA molecular carries out sequencing, greatly improves sequencing efficiency.This kind of large scale sequencing technology greatly improves multiple objects The solution reading rate of kind hereditary information, to obtain the sequence information of all miRNA, decryption miRNA collection of illustrative plates provides guarantee.It is high simultaneously Flux sequencing to carry out the analysis of careful overall picture to the transcript profile and genome of species, so being otherwise known as Deep sequencing (deep sequencing).The representative of high-flux sequence platform is 454 sequenators of Roche Holding Ag (Roche) (Roch GSFLX sequencer), Solexa genome analysis instrument (the Illumina Genome of Illumina companies ) and the SOLiD sequenators of ABI (ABI SOLiD sequencer) Analyzer.

The acquired technology of microRNA functions based on RNA be the precursor substance that is synthesized by exogenous supplement miRNAs come Increase the level of miRNAs.For example, can the artificial synthesized bob folder sample RNA (short consistent with endogenous miRNA sequence Hairpin RNA, shRNA), promoter is done by polymerase II or III, with virus for carrier transfectional cell, by Dicer enzyme modifications It is loaded into RISC afterwards to play a role, is equivalent to the level for increasing pre-miRNA, function and effect are stable and lasting.

This technique avoids the nonspecific actions of miRNA and gene for gene specific miR Mimics technologies.This people The specific oligonucleotide chain of work synthesis combined with 3 ' UTR complementations of target gene, is adjusted after capable of playing transcription identical with miRNA Section acts on.

The carrier permitted in the pharmacy of the pharmaceutical composition of the present invention is the load usually utilized in preparation Body, which includes lactose (lactose), dextrose (dextrose), sucrose (sucrose), sorbierite (sorbitol), sweet Reveal alcohol (mannitol), starch, acacia gum, calcium phosphate, alginates (alginate), gel (gelatin), calcium silicates, Microcrystalline cellulose, polyvinylpyrrolidone (polyvinylpyrrolidone), cellulose (cellulose), water, syrup, first Base cellulose (methyl cellulose), methyl hydroxybenzoate (methyl hydroxybenzoate), propyl hydroxy benzene Propyl formate (propyl hydroxybenzoate), talcum, magnesium stearate (stearic acid magnesium) and mineral Oily (mineral oil) etc., but it is not limited to this.

The pharmaceutical composition of the present invention can also include lubricant, wetting agent, sweetener, perfume (or spice) other than mentioned component Taste agent, emulsifier, suspending agent, preservative etc..The suitable carrier and preparation permitted in pharmacy is recorded in Lei Mingdengshi in detail Pharmacy pandect.

The pharmaceutical composition of the present invention can by it is oral or it is non-oral be administered, when as non-oral administration, can lead to Cross intravenous injection, intranasal injection, local injection, intraventricular injection, spinal cavity injection is subcutaneously injected, intraperitoneal injection, percutaneously The modes such as administration are administered.

The present invention pharmaceutical composition suitable dosage according to preparation ways, administering mode, patient year The factor of age, weight, gender, morbid state, food, administration time, administration route, drainage rate and draw property etc and can be with Carry out a variety of prescriptions, in general, skilled practitioner can be easily determined by and prescription to it is desirable treatment or prevention effectively to Pharmaceutical quantities.

The pharmaceutical composition of the present invention can be easy to implement according to general technical staff of the technical field of the invention Method, carried out using receptible carrier in pharmacy and/or excipient it is formulation, so as in the form of unit dose It prepares or interior prepares in the multicapacity container.At this point, dosage form be solution in oiliness or aqueous medium, suspension or Emulsion form can also be either extract, powder agent, granule, tablet or capsule form, can also include dispersion Agent or stabilizer.

Description of the drawings

Fig. 1 RT-PCR detection each group C4B genes and ENSG00000233627 expressions

Fig. 2 RT-PCR detect each group miRNA expressions

Specific implementation mode

Present invention will be further explained below with reference to specific examples, is only used for explaining the present invention, and should not be understood as to this The limitation of invention.It will be understood by those skilled in the art that：Without departing from the principle and spirit of the present invention may be used To carry out a variety of change, modification, replacement and modification to these embodiments, the scope of the present invention is limited by claim and its equivalent It is fixed.In the following examples, the experimental methods for specific conditions are not specified, usually according to normal condition or according to the item proposed by manufacturer Part examinations.

The collection of 1 sample of embodiment and Total RNAs extraction

3 metastatic bone sarcoma patients, 3 primary Patients with Osteosarcoma and 3 Healthy Peoples.Transfer group chooses metastases Lesion, metastasis site are lung, primary group of selection tumour primary lesion, and normal healthy controls choose amputation sample.All blood sample and Pathological examination answer it is true and reliable, research ratify through Ethics Committee, patient's informed consent.

RNA extraction standards：RNA purity：OD260/280≤1.8,28S/18S≤1；RNA integralities：Zhi≤7.0 RIN. RNA integrality detection methods：Agilent 2100 (RNA 6000Nano kit), (Ago-Gel is dense for agarose gel electrophoresis Degree：1% agarose gel；Voltage：5V/cm；Time：20min).

LncRNA and mRNA sequencings require：

Sample requirements：≥200ng；Sample concentration：C≥20ng/μL；Sample purity：RIN≥7.0,28S/18S≥ 1.0。

MiRNA sequencings require：

Sample requirements (single)：≥1μg；Sample concentration：15ng/μL≤c≤500ng/μL；Sample purity：OD260/ 280=1.8~2.2；OD260/230≥2.0；28S:18S≥1.5；RIN≥8.0.

Embodiment 2 is sequenced and data analysis

Sequencing：

LncRNA and mRNA microarray datasets：Hiseq2500 125PE complete the chain specific transcriptional group sequencing of 9 people (lncRNA), the output of each sample is not less than 10Gb data.

MiRNA microarray datasets：Hiseq4000 50SE complete the small RNA sequencings of 9 human tissue samples, each sample The generation of product is not less than 10M reads data.

MRNA and lncRNA analyses：

1tophat is compared onto reference gene group, and reference gene group comes from Ensembl V84；

2.cuffquant quantifies the expression quantity and normalization output of lncRNA and mRNA；

3.cuffdiff packets compare the differential expression of lncRNA and mRNA between two groups.

MiRNA is analyzed：

1. after obtaining original FASTQ data, Quality Control being carried out to it and obtains sequencing result (the clean small of high quality RNA), and sequence length distribution statistics are carried out.Use software：Fastx-Toolkit(http://hannonlab.cshl.edu/ fastx_toolkit/).Steps are as follows for Quality Control：(1) the lower base of shearing sequencing quality (mass value is less than 20)；(2) it removes Since connector leads to the reads for being not inserted into segment due to connect etc.；(3) reads containing N is removed；(4) small fragment is removed (being less than 18bp)；(5) sequence that extraction length is 18-32bp；(6) clean small RNA distribution of lengths counts.

2. with bowtie on reads map to genome.It is downloaded under ripe miRNA and miRNA precursor sequences MiRBase, reference gene group are GRCh38；

3. with the expression of the quantitative known miRNA of miRDeep2；

4. comparing with DEGseq packets two groups of differential expression under R environment.

Screening criteria P<0.01, abs (log2 (fold change))>2；307 difference expression genes (106 are screened Up-regulation, 201 lower)；50 differential expression lncRNA (27 up-regulations, 23 lower)；(19 raise 48 differential expression miRNA, under 29 It adjusts).After comprehensive analysis and artificial screening, C4B genes and non-coding RNA-ENSG00000233627, the miR- for regulating and controlling its expression 1197, miR-1269a, miR-182-5p enter our research range.C4B genes express (transfer group VS originals in transfer group height Hair group), but primary group between healthy control group but without difference, show that it is only related to bone and flesh tumor metastasis, C4B genes are The nearby gene of long-chain non-coding RNA-ENSG00000233627, the two coexpression correlation are up to 99.5%, simultaneously number According to analysis shows that and lncRNA target gene, using including RNAhybrid, miRWalk, PICTAR2 and Targetscan The target base of the targeting lncRNA, miR-1197, miR-1269a, miR-182-5p of these 4 kinds of algorithm forecasted variances expression miRNA Because being ENSG00000233627.

Embodiment 3Real-time PCR detect C4B genes in osteosarcoma sample and regulate and control the non-coding RNA that it is expressed Expression

1 sample collection：

The peripheral blood of 14 metastatic bone sarcoma tumor patients, 15 primary Patients with Osteosarcoma and 20 normal healthy controls come From hospital.

2 Total RNAs extractions：

The processing for removing Rnase of related experiment article：

1. by bubble, 120 DEG C of high pressure 20min is invaded with DEPC flushings before the application of all glasswares, 180 DEG C of high temperature dry 2 Hour or more.

2. (such as by plastic ware：EP pipes/pipette tips) need before use with 0.1%DEPC water enchroachment (invasion)s bubble overnight, after drain liquid, 120 DEG C of high pressure 20min, oven is dried spare.

Leucocyte detaches

(1) 2m1 anticoagulation cirumferential bloods are taken (blood sampling time is no more than 3h)；

(2) isometric sterile PB S are added to be sufficiently mixed in peripheral blood, form cell suspension；

(3) 4m1 lymphocyte separation mediums are added in another centrifuge tube；

(4) draw 4m1 cell suspensions be gently added to along tube wall lymphocyte separation medium surface (pay attention to not with lymphocyte Separating liquid mixes).Centrifuge 1500rpm 20min；

(5) boundary layer (tunica albuginea) is gently sucked out with suction pipe to enter in another centrifuge tube.Sterile cold PBS is washed 2 times, is washed for last 1 time Washing can move into cell suspension in EP pipes, and supernatant is removed in centrifugation, for extracting RNA.

RNA is extracted

(1) first add lml Trizol in EP pipes, if freeze-stored cell is directly added into Trizol, be not required to thaw, piping and druming cracking After be stored at room temperature 5-l0min；

(2) 0.2m1 chloroforms are added, acutely shakes 15s, is stored at room temperature 2-3min, 1 2000 leave heart 15min at 4 DEG C；

(3) the supernatant water 600ul that makes an appointment carefully is sucked out and moves into another centrifuge tube (being careful not to be extracted into albumin layer), is added 500： 1 isopropanol overturns mixing, is stored at room temperature 10min；

(4) 4 DEG C of 1 2000g centrifuge l 0min, abandon supernatant, bottom visible white substance；

(5) the rotation washing of 75% cold ethyl alcohol of lml is added, cleans isopropanol；

(6) 4 DEG C of 7500g centrifuge 5min, and dry in the air 5-l0min after removal ethyl alcohol, translucent, with 20u1DEPC water dissolutions RNA.3u1RNA samples are taken, the electrophoresis in 1.5% Ago-Gel；Lu1RNA samples in UV spectrophotometer measuring concentration, It is considered as RNA sample qualifications in 1.8-2.0 with A260/280.

3 reverse transcriptions

MRNA reverse transcriptions：

It takes 1 μ g total serum IgEs as template ribonucleic acid, usesIII Reverse Transcriptase (invitrogen, article No. 18080-044) carries out cDNA reverse transcriptions, and experimental implementation is carried out by product description.The cDNA of acquisition It is spare that -20 DEG C of refrigerators are put in preservation.

MiRNA reverse transcriptions：

The preparation of RT systems：1 μ g total serum IgEs are as template ribonucleic acid；5×miScript HiSpec Buffer 4μl；10× Nucleics Mix 2μl；miScript Reverse Transcriptase Mix 2μl；Aqua sterilisa filling-in is to 20 μ l.ABI After 37 DEG C of heat preservation 60min keep reverse transcription reaction complete in 9700 type PCR instruments, 95 DEG C of 5min terminate reaction.80 μ l are added Nuclease-free H₂O is diluted to 100 μ l, and to be stored in -20 DEG C of refrigerators spare.

4 quantitative fluorescent PCRs

Design of primers：

ENSG00000233627

Sense primer：5’-GTAACTGGAAGAAGACACT-3’(SEQ ID NO 5)

Downstream primer：5’-ACGCTTGGTTCTGTTATC-3’(SEQ ID NO 6)

miR-1197

Specific primer：5’-TAGGACACATGGTCTACTTCT-3’(SEQ ID NO 7)

miR-1269a

Specific primer：5’-CTGGACTGAGCCGTGCTACTGG-3’(SEQ ID NO 8)

miR-182-5p

Specific primer：5’-TTTGGCAATGGTAGAACTCACACT-3’(SEQ ID NO 9)

C4B genes (NM_001002029.3)

Sense primer：5’-ACCTACAGATAGAAGTGA-3’(SEQ ID NO 10)

Downstream primer：5’-CTCATAGTCCTCATAGTC-3’(SEQ ID NO 11)

The preparation of the RT-PCR systems of mRNA and lncRNA：

Reactive component	Concentration	Volume (μ l)
			mix	2×	10
Sense primer	10uM	0.5
			Downstream primer	10uM	0.5
cDNA	-	2
			Nuclease-free H₂O	-	Filling-in is to 25 μ l

3 parallel tube reactions are arranged in the detection of expression of mRNAs every time, using actin as internal reference.

Amplification program is：95 ° of 10min, 45 cycles (95 DEG C of 15s, 55 DEG C of 60s).

The preparation of the RT-PCR systems of miRNA：

3 parallel tube reactions are arranged in the detection of expression of miRNAs every time, using snRNA U6 as internal reference.

Amplification program：95℃10min；40 cycles (95 DEG C of 10s, 60 DEG C of 30s).

5 statistical analysis

Real-time quantitative PCR amplification curve inflection point understands that amplification curve entirety collimation is good, shows the amplification effect of each reaction tube Rate is close, and the limit is flat and present without raising up, and exponent phase slope is larger, illustrates that amplification efficiency is higher；Sample amplified production is molten Solution curve is all unimodal, illustrates that amplified production only has one, is specific amplification；According to the relative quantification formula of qRT-PCR：2- Δ Ct × 100% compares C4B genes and ENSG00000233627 in primary group of osteosarcoma, transfer group group and Normal group Expression.As a result it shows：It is expressed in osteosarcoma transfer group height relative to primary group of C4B gene and ENSG00000233627, Expression quantity respectively at 6.7 times and 3.1 times or so, the two primary group between control group differential expression it is not statistically significant (specific See attached drawing 1).MiR-1269a is at 7.0 times that the expression quantity of osteosarcoma transfer group is about primary group, miR-1197, miR-182-5p In osteosarcoma transfer group low expression, the half and 1/9th or so of respectively primary group expression, they are primary Differential expression is not statistically significant between group and control group (being specifically shown in attached drawing 2), and result above demonstrates high-throughput transcript profile expression The result of the confluence analysis of data.

Embodiment 4miR-1269a is verified with osteosarcoma transfer relationship

One, material prepares：

(1) Specimen origin

Human osteosarcoma cell line MG-63 is purchased from Shanghai cell research institute of the Chinese Academy of Sciences.

(2) main agents

Lipofectamine^TM2000Transfection Reagent(Invitrogen)。

MiR-1269a sequences issue Ji Ma genome companies, ask its chemical synthesis miR-1269a mimics, miR-1269a Inhibitor and non specific control.

(3) main solution

1, cell culture fluid

+ 10% standard fetal calf serum of DMEM culture mediums.

2, PBS (balanced salt solution)

8g NaCl, 0.25g KCl, 1.44g Na are dissolved in 800m1 distilled water₂HPO₄With 0.24g KH2PO4 HCl The pH value of solution is adjusted to 7.4, water is added to be settled to 1L, high pressure sterilization, room temperature preservation.

3,0.25% tryptic digestive juice

0.25g trypsase is added in 100m1 deionized waters, filter filtration sterilization, and packing is spare.

Two, experimental method

1, cell passes on

(1) culture solution original in the culture bottle for covering with cell is discarded, 0.25% trypsin solution 1m1, covering is added Cellular layer, bottleneck disinfection, capping；

(2) cellular change is observed under inverted microscope, over time, former adherent cell gradually tends to be round, Cytoplasm bounces back, and space between cells increases, and discards pancreatin in also non-levitating, and the culture that 5ml contains 10% fetal calf serum is added Liquid terminates digestion；

(3) cell count：Above-mentioned cell suspension 0.5mI is taken, is instilled in blood cell counting plate after appropriate dilution, by leucocyte Counting method number quadrangle four big lattice inner cell sum, when counting, only count nucleus and the complete cell of cytoplasm, cell in heaps It is calculated by a cell, by the total number of cells in 4 block plaids by following formula scales at the cell number in every milliliter of cell suspension： Big lattice total number of cells/4 × 10 total number of cells/ml=4⁴× extension rate；

(4) it according to cell counts, is further diluted to every milliliter with DMEM complete culture solutions and contains 3 × 10⁵A cell Concentration is sub-packed in culture bottle (every bottle of 8m1/), is positioned over 37 DEG C, 5%CO₂It is cultivated in incubator.2.miRNA is transiently transfected

It is transiently transfected, is operated according to Lipofectamin using cationic-liposome method^TM2000 reagent specifications into Row.For 24 hours by growth conditions good cell inoculation to 12 orifice plates before transfection, cell count about 2 × 10⁴, routine culture to turn The dye same day, cell fusion degree are tested when being 50-60%.20nM/40nM/80nMmiRNA mimic are added to In 100u1DMEM culture mediums, soft mixing；Separately 2u1Lipofectamin is diluted with 100u1DMEM culture mediums^TM2000 liposomes, Soft mixing is incubated at room temperature 5min；DMEM- liposomes and DMEM-miRNAs are mixed, 20min is incubated at room temperature, it is multiple to form transfection Close object；Then said mixture is added in cell culture medium, gently mixing, complete medium is replaced after cultivating 6h.Wherein, non- Specific sequence only transfects liposome as negative control, blank control.Extraction cell total rna carries out in next step after cultivating 48h Experiment.

3.Transwell migration experiments

Detect cell migration situation when, first use trypsin digestion cell, and the culture medium that serum-free is added prepare it is slender Born of the same parents' suspension；By 1 × 10⁵A cell inoculation is in interior cultures of the placement 600u1 containing 10%FBS in the small interiors Transwell, lower layer Base is placed in 37 DEG C, 5%CO₂Cell incubator in cultivate；The cell scraper for using cotton swab carefully not migrate small interior afterwards for 24 hours Fall；Absolute methanol fixes 1-5min, and cell overturning is dried；Using 0.1% violet staining 20min；It is cleaned 2 times using PBS； Cell is transferred in 24 orifice plates containing PBS；Cell migration situation is observed under inverted microscope, takes the 6-8 visual field at random, into Row cell count.

The number for being overexpressed the MG63 cell migrations of miR-1269a is significantly higher than blank control group (p<0.05), inhibit The MG63 cell migration numbers of miR-1269a expression are substantially less than blank control group (p<0.05) it is thin that miR-1269a groups, are overexpressed It is 305 that born of the same parents, which migrate number, and it is 152 to inhibit miR-1269a expression group cell migration numbers, blank control group cell migration number Mesh is 187, and negative control group (transfection non-specific sequences) cell migration number is 190, with blank control group without statistics Learn difference.

Although having referred to various preferred embodiments describes the present invention, it will be appreciated by those skilled in the art that can carry out each Kind variation, and available equivalents substitute base region of its component without departing from the present invention.Come in addition, many changes can be carried out Specific condition or material is set to be suitable for the teachings of the present invention without departing from its base region.

Therefore, the present invention is not intended to be defined in the particular embodiment disclosed herein for carrying out the present invention；On the contrary, This invention is intended to all embodiments including falling within the scope of the appended claims.

Sequence table

<110>Beijing Yang Shen biology information technologies Co., Ltd

<120>Regulate and control the non-coding RNA and application thereof of C4B gene expressions

<160> 11

<170> SIPOSequenceListing 1.0

<210> 1

<211> 2095

<212> RNA

<213>People (Homo sapiens)

<400> 1

agcgaugagc ccuggaguga gcagcuguau cucuggcacc uggcacaggg cauggcauga 60

agugaaagau ucccgaauuu cugucgaaug acuggauggc aggcugcuga acugucauga 120

ccucuacgga aacugaucuc accaaacuuc uuuggacaga cgcggaguca ucucugaaga 180

ccccaggugu gccacuaaau gggggaaagu uaggcagguc cggugggaag gggagacccc 240

aggagaacag cggcuuccuc agaggauuca caaacacacc aaagucagac uuuuggcuug 300

uuugaaacca guaacuggaa gaagacacug ccggaccuga ggauugcaca acuccgggaa 360

agucaccuca uuccacugau aacagaacca agcgucagca ggcuuucaac agcccggaac 420

ucagcuaaaa ucugcagacc ucagaaccgc cagcagcacg aggacagagu cggggaggug 480

uagcuggaca acagcucaug aggcaaacuu cauccuguag ccauccucgu ccugcagacc 540

ccgcuccagg gcgcgacgcu ggcgagggca cuucccugaa guuggggaac ccaucagaca 600

gugugggggg ggccccggcc aucccgccuc cacugccccg ccccaggccc ucagucucac 660

ccucagcaca cuggcagacu ucagcagaac acaagguggc caagagucug cucuuacuug 720

gugccccgua aaacacagaa caucugcgcu cuggagaaca gagaggaguu agggcacagg 780

ccccuccauu cugccuccuc agucccaggg agccccaggg cucucugccc ccucacuacc 840

ccggugucca uugucccaua ggagggcacc uaugccaaag uucuccugaa uuucagggug 900

uccugcagug cucaccgggg uuguaguagu cguacagggu ugcgcuggcc ggcugcacca 960

gccccaccgg cacuuccugc acagccucaa agcccacgca cucccgggag guggggaccu 1020

ggccaagcgu ggggaggaga gaugagggac ccacucccug ggcccugcag cccccuguac 1080

uggguuuccu uggccuguuu uuguuugcuu ccuauuggcc uucucuccag uguccuucac 1140

auucuguuac cuuccuacuc agagaacucu caaagcugcu ccgcaagguc ucuggugacu 1200

ucacuuccca gagggugacc uugccccagu cuucacugcu ccaggcccuc agcagagucu 1260

ugcaucaugg acguguucuc ugugaaacug ucccuaagcu aaggguuagc uucuggacca 1320

cccuugguuc ugaccugguc auuucuuacg uucccuccuu cggaacuucc uuccucagag 1380

cuccccugug ggggucucaa ccacucccug gcuuccacca aaccaaucca ggcugaugau 1440

ucccaaacug aacuugcagc uccauccuug cauuaggauu guggcaggac cuguaaguuc 1500

uccaaggcac ucugccugcc cccaaaccca cucgcccucc ucgcggccuc aucuuuguca 1560

uggauacaac uggguccucc uuuauuugcc acaaccuaac ugcagguucu gucauccugc 1620

cugacccccc gacucagguc ccaggccuga ccccuccucg ugcccacgcg ggcccagucc 1680

acacggugcc gugccagugu cccuccugag cuaggcugcu gcaccgucag cucccuaucc 1740

gggaaucuug uuggcucugu guuuucuauu guguucaacc cagauguguc agccaggcuu 1800

ccccagcuga ugggggcugg ccccucugca cacacugggu aggggucucc cugaccuaca 1860

aacagcuggc uaaugacagc caccacaccu uucucacauu uucucccaga gguuacagua 1920

aauguuccaa aacuuuuuuu gaaggccggg caugguggcu cuggccugua aauccgguac 1980

uuugaaaggc cuaggccaga ggaucgcuug aggccgggag uucaagacca gccugggcaa 2040

cagagcgaga cccugucuuu acuaaauaaa uaaauaaaaa uguuuugaga gccgu 2095

<210> 2

<211> 21

<212> RNA

<213>People (Homo sapiens)

<400> 2

uaggacacau ggucuacuuc u 21

<210> 3

<211> 22

<212> RNA

<213>People (Homo sapiens)

<400> 3

cuggacugag ccgugcuacu gg 22

<210> 4

<211> 24

<212> RNA

<213>People (Homo sapiens)

<400> 4

uuuggcaaug guagaacuca cacu 24

<210> 5

<211> 19

<212> DNA

<213>Artificial sequence (Artificial Sequence)

<400> 5

gtaactggaa gaagacact 19

<210> 6

<211> 18

<212> DNA

<213>Artificial sequence (Artificial Sequence)

<400> 6

acgcttggtt ctgttatc 18

<210> 7

<211> 21

<212> DNA

<213>Artificial sequence (Artificial Sequence)

<400> 7

taggacacat ggtctacttc t 21

<210> 8

<211> 22

<212> DNA

<213>Artificial sequence (Artificial Sequence)

<400> 8

ctggactgag ccgtgctact gg 22

<210> 9

<211> 24

<212> DNA

<213>Artificial sequence (Artificial Sequence)

<400> 9

tttggcaatg gtagaactca cact 24

<210> 10

<211> 18

<212> DNA

<213>Artificial sequence (Artificial Sequence)

<400> 10

acctacagat agaagtga 18

<210> 11

<211> 18

<212> DNA

<213>Artificial sequence (Artificial Sequence)

<400> 11

ctcatagtcc tcatagtc 18

Claims

1. detection C4B genes or the non-coding RNA preparation for regulating and controlling its expression are preparing the application in diagnosing osteosarcoma transfering reagent, The non-coding RNA is ENSG00000233627 or targets the miRNA of ENSG00000233627.

2. application according to claim 1, which is characterized in that miRNA miR-1197, miR-1269a or miR-182- 5p。

3. application according to claim 1, which is characterized in that diagnosis osteosarcoma transfering reagent includes being based on high-flux sequence Method and/or based on quantifying PCR method and/or based on probing procedure detection sample in C4B, ENSG00000233627, MiR-1197, miR-1269a or miR-182-5p transcribe or are detected based on immunologic detection method the expression feelings of C4B albumen in sample Condition.

4. application according to claim 1, which is characterized in that using northern hybridizing methods, miRNA express spectra cores C4B, ENSG000 in piece, ribozyme protection analytical technology, RAKE methods, in situ hybridization, bead-based flow-cytometry detection sample 00233627, the transcription of miR-1197, miR-1269a or miR-182-5p；It is detected using ELISA and/or colloidal gold strip The expression of C4B albumen in sample.

5. application according to claim 3, which is characterized in that based on quantifying PCR method include specific amplification C4B, The primer of ENSG00000233627, miR-1197, miR-1269a or miR-182-5p；Based on probing procedure include with The probe of the nucleic acid array hybridizing of C4B, ENSG00000233627, miR-1197, miR-1269a or miR-182-5p；It is described to exempt from Epidemic disease detection method includes the antibody combined with C4B protein-specifics.

6. a kind of prevention osteosarcoma transfering reagent, including lower the transcription of miR-1269a and/or inhibit the activity of miR-1269a Reagent, either lower ENSG00000233627 transcription and/or inhibit ENSG00000233627 active reagent or It raises the transcription of miR-1197 or miR-182-5p and/or promotes the active reagents of miR-1197 or miR-182-5p.

7. prevention osteosarcoma transfering reagent according to claim 6, which is characterized in that miRNA inhibitor, using antisense widow Nucleotide, antagomiRs, miRNA sponge, miRNA Erasers, TargetMasking and/or multiple target point antisense oligonucleotides The method of acid lowers the transcription of miR-1269a and/or blocks the activity of miR-1269a；Or under siRNA or structure interference carrier It adjusts the transcription of ENSG00000233627 and/or inhibits the activity of ENSG00000233627.

8. prevention osteosarcoma transfering reagent according to claim 6, which is characterized in that use the microRNA based on RNA The acquired technology of function and/or gene specific miR Mimics technologies up-regulation miR-1197 or miR-182-5p transcription and/ Or promote the activity of miR-1197 or miR-182-5p.

9. the prevention osteosarcoma transfering reagent according to claim 6-8 any one, which is characterized in that also include pharmacy Upper receptible carrier.

10. prevention osteosarcoma transfering reagent described in claim 6-9 any one prepare treatment osteosarcoma diversion medicaments or Application in preparation.